Neurochemical Research

, Volume 32, Issue 4, pp 635–638

Effects of Thiazolidinediones on Stroke Recovery: A Case-Matched Controlled Study

Original Paper

DOI: 10.1007/s11064-006-9138-3

Cite this article as:
Lee, J. & Reding, M. Neurochem Res (2007) 32: 635. doi:10.1007/s11064-006-9138-3


Background and purpose

Anti-inflammatory therapy decreases infarct size and enhances stroke recovery. Thiazolidinedione peroxisome proliferator-activated receptor (PPAR)gamma agonists have potent anti-inflammatory and insulin-sensitizing anti-diabetic actions.


Thirty stroke patients with type 2 diabetes admitted for acute inpatient stroke rehabilitation receiving pioglitazone or rosiglitazone were matched for age, sex, initial FIMTM score and interval post-stroke with 30 stroke patients with type 2 diabetes not receiving thiazolidinediones. Relevant outcome variables were compared for both groups.


The thiazolidinedione treated group showed significantly greater mean improvement in FIMTM score compared to control group (25.6 ± 10.2 SD vs. 19.8 ± 10.5, respectively, = 0.015). There was no significant difference in length of rehabilitation hospital stay (24.2 ± 7.6 vs. 25.1 ± 7.4 days, = 0.657) or final discharge destination (home/institution, 19/11 versus 17/13, = 0.792).


Use of thiazolidinediones was associated with enhanced functional recovery in stroke patients with type 2 diabetes.


Thiazolidinedione PPARgamma Stroke Diabetes mellitus Functional recovery 

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of Rehabilitation Medicine, Konkuk University Hospital and Center for Geriatric Neuroscience Research, Institute of Biomedical Science and TechnologyKonkuk UniversitySeoulSouth Korea
  2. 2.Department of NeurologyWeill Medical College of Cornell University at Burke Rehabilitation HospitalWhite PlainsUSA

Personalised recommendations